
US Patent Application No: 2002/0013,264
Number of patents in Portfolio can not be more than 2000
Neoglycan anticancer agents and uses thereof
Stats
-
Jan 31, 2002
Publication date -
Aug 2, 2001
filing date -
09/921,032
serial no -
ABAN
status
Importance
Abstract
The instant invention describes the production of neoglycans, compounds capable of inhibiting tumor cell growth. The heparan sulfate proteoglycan syndecan-1 is a tumor suppressor molecule that inhibits growth and induces apoptosis in several cancer cell lines. Attempts to create synthetic analogues of syndecan-1 by carbodiimide (EDAC) conjugation of a protein scaffold and GAG surprisingly revealed that the protein component is not required. Neoglycans consisting of EDAC-modified heparin and EDAC-modified chondroitin sulfate (CS), respectively named neoheparin and neo-chondroitin sulfate (neoCS), were found to inhibit multiple myeloma cell viability. Further analysis revealed the neoglycan compounds severely reduced cell viability of multiple myeloma, breast cancer and normal laboratory cell lines and peripheral blood mononuclear cells through the induction of apoptosis. Neoglycans provide a new class of GAG chain-based anticancer therapeutics.
First Claim
Related Publications
International Classification(s)
- [Classification Symbol]
- [Patents Count]